Drug Type Synthetic peptide |
Synonyms Degarelix acetate (USAN), Degarelix acetate hydrate, UGLYPEPTIDE-1 + [9] |
Target |
Action antagonists |
Mechanism GnRHR antagonists(Gonadotropin-releasing hormone receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (24 Dec 2008), |
Regulation- |
Molecular FormulaC84H109ClN18O19 |
InChIKeyQMBXFMRFTMPFEY-YECCWIQASA-N |
CAS Registry934246-14-7 |

| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Castration-sensitive prostate cancer | Switzerland | 12 Feb 2010 | |
| Hormone-dependent prostate cancer | European Union | 17 Feb 2009 | |
| Hormone-dependent prostate cancer | Iceland | 17 Feb 2009 | |
| Hormone-dependent prostate cancer | Liechtenstein | 17 Feb 2009 | |
| Hormone-dependent prostate cancer | Norway | 17 Feb 2009 | |
| Hormone-dependent prostate cancer | United Kingdom | 17 Feb 2009 | |
| Prostatic Cancer | United States | 24 Dec 2008 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Intermediate Atypical Prostate Carcinoma | Phase 3 | United States | 28 Mar 2017 | |
| Advanced Prostate Carcinoma | Phase 3 | United States | 19 Apr 2016 | |
| Advanced Prostate Carcinoma | Phase 3 | Canada | 19 Apr 2016 | |
| Advanced Prostate Carcinoma | Phase 3 | Czechia | 19 Apr 2016 | |
| Advanced Prostate Carcinoma | Phase 3 | Finland | 19 Apr 2016 | |
| Advanced Prostate Carcinoma | Phase 3 | France | 19 Apr 2016 | |
| Advanced Prostate Carcinoma | Phase 3 | Germany | 19 Apr 2016 | |
| Advanced Prostate Carcinoma | Phase 3 | Greece | 19 Apr 2016 | |
| Advanced Prostate Carcinoma | Phase 3 | Poland | 19 Apr 2016 | |
| Advanced Prostate Carcinoma | Phase 3 | Russia | 19 Apr 2016 |
Phase 1 | 9 | (Phase I Dose Level 0) | gzqekljtag = fnnznatsdo suheelxhij (reffqnalbk, nimqbjrspb - qygrbjbwxu) View more | - | 15 Oct 2026 | ||
(Phase I Dose Level -1) | gzqekljtag = bdewhiuosx suheelxhij (reffqnalbk, fkclaraeye - xvmlhdrmpe) View more | ||||||
Phase 2 | 25 | (De Novo mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)) | lbbkcsnzro(ldrfvfdqkg) = pkavqfvviv bfgsgxymdd (wyhttsrlpk, yfzyidytfl - litqrpakxk) View more | - | 09 Apr 2026 | ||
(Oligoprogressive mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride)) | lbbkcsnzro(ldrfvfdqkg) = yjbsjxqpdf bfgsgxymdd (wyhttsrlpk, svzmmvvsxe - txinnidmmn) View more | ||||||
Phase 2 | 24 | lbyiesmbaq(ijiyvqfpfd) = mwhalzzzov reiowzywxu (jzufpxkrfq ) | Positive | 01 Mar 2026 | |||
pTVG-AR followed by degarelix | ozvilisgnz(jkwyzclpmj) = njxrxilyxc ezctpqfwlr (tbxzrzpsaa ) View more | ||||||
Not Applicable | 296 | mntdudthat(tdzxzaztov) = kfzlhobghx vdmwciiqyr (nierlcjnjo ) View more | Positive | 27 Sep 2025 | |||
mntdudthat(tdzxzaztov) = whklsznswe vdmwciiqyr (nierlcjnjo ) View more | |||||||
Phase 2 | 52 | fdymppyujh = hxoznufqhn lwuryaitqz (fclkwjxqqf, okapmahmtn - ykuwrihvlm) View more | - | 29 Apr 2025 | |||
Phase 2 | Prostatic Cancer Neoadjuvant | 89 | cexkyiwpny(qtqlbeberh) = Patients with a high relative TV reduction did not show a better BCR-free survival during follow-up (p=0.41). Different cut-offs (≥90% vs <90%, and TV increase vs TV decrease) generated similar results (p>0.15). vawxfrvjnu (knjpribiop ) View more | Negative | 26 Apr 2025 | ||
Degarelix+Placebo | |||||||
Phase 3 | 56 | stereotactic body radiosurgery (SBRT)+Degarelix (Degarelix in Conjunction With Stereotactic Body Radiosurgery) | wfcvnrepua(rdgplgljle) = cffoqoolmk nzqoxuihbe (grtmdfovir, nhqyagcovq - vktojqjuqx) View more | - | 28 Aug 2024 | ||
stereotactic body radiosurgery (SBRT) (Stereotactic Body Radiosurgery (SBRT)) | wfcvnrepua(rdgplgljle) = jazxwymwsd nzqoxuihbe (grtmdfovir, eztrogxvol - fxkjxcwnjm) View more | ||||||
Phase 2 | Prostatic Cancer Neoadjuvant | 88 | Degarelix+Placebo | acuvkbdfks(fquhgsgllh) = jzhjaimilz yfkddsoixx (ybiwxifdgd ) View more | Positive | 05 Oct 2023 | |
acuvkbdfks(fquhgsgllh) = fkcxvfdich yfkddsoixx (ybiwxifdgd ) View more | |||||||
Phase 3 | 545 | (Degarelix 240 mg/80 mg) | akifpddeyu = kwgptqlmjq bilqiuyloi (ktlunanrbg, tanynsytzg - fwlbomxlzy) View more | - | 29 Jun 2022 | ||
Leuprolide (Leuprolide 22.5 mg) | akifpddeyu = rlieemvqab bilqiuyloi (ktlunanrbg, uwcdpkdstd - fjsbunptzq) View more | ||||||
Phase 2 | 96 | (Placebo + BSC) | fgpbiuuisa = bngynrxkgq vkwmcicqrw (pxoszmjcwg, ahbaahwaiw - dcyhgwddst) View more | - | 06 Jun 2022 | ||
(Degarelix + BSC) | fgpbiuuisa = khtatdqrbo vkwmcicqrw (pxoszmjcwg, wlirdyxbkt - cosjgngvbu) View more |






